Central disorders of hypersomnolence US Medical PG Practice Questions and MCQs
Practice US Medical PG questions for Central disorders of hypersomnolence. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Central disorders of hypersomnolence US Medical PG Question 1: An otherwise healthy 55-year-old woman comes to the physician because of a 7-month history of insomnia. She has difficulty initiating sleep, and her sleep onset latency is normally about 1 hour. She takes melatonin most nights. The physician gives the following recommendations: leave the bedroom when unable to fall asleep within 20 minutes to read or listen to music; return only when sleepy; avoid daytime napping. These recommendations are best classified as which of the following?
- A. Cognitive behavioral therapy
- B. Relaxation
- C. Improved sleep hygiene
- D. Stimulus control therapy (Correct Answer)
- E. Sleep restriction
Central disorders of hypersomnolence Explanation: ***Stimulus control therapy***
- This therapy focuses on **removing cues** that hinder sleep and **establishing a strong association** between the bed/bedroom and sleep.
- The recommendations (leaving the bedroom when awake, returning only when sleepy, avoiding daytime naps) are classic components of **stimulus control therapy** for insomnia.
*Cognitive behavioral therapy*
- **CBT-I** is a comprehensive approach that includes stimulus control, sleep hygiene, relaxation techniques, and cognitive restructuring.
- While stimulus control is a part of CBT-I, the recommendations provided are specifically designed to address conditioning and are thus best classified as stimulus control therapy.
*Relaxation*
- Relaxation techniques involve methods like **progressive muscle relaxation**, **deep breathing exercises**, or **meditation** to reduce physiological arousal.
- The given recommendations do not directly involve these types of activities but rather focus on changing behaviors around sleep.
*Improved sleep hygiene*
- Sleep hygiene involves practices that promote good sleep, such as maintaining a **regular sleep schedule**, ensuring a **comfortable sleep environment**, and **avoiding caffeine/alcohol** before bed.
- While avoiding daytime naps is related to sleep hygiene, the core recommendations (leaving the bedroom when awake, returning only when sleepy) specifically target conditional associations with the bed, making them more characteristic of stimulus control.
*Sleep restriction*
- Sleep restriction therapy involves **limiting the time spent in bed** to the actual time asleep, with the goal of building up sleep drive and improving sleep efficiency.
- The recommendations given do not specify a fixed reduction in time allowed in bed but rather focus on behavioral responses to wakefulness in bed.
Central disorders of hypersomnolence US Medical PG Question 2: A 20-year-old female presents to student health at her university for excessive daytime sleepiness. She states that her sleepiness has caused her to fall asleep in all of her classes for the last semester, and that her grades are suffering as a result. She states that she normally gets 7 hours of sleep per night, and notes that when she falls asleep during the day, she immediately starts having dreams. She denies any cataplexy. A polysomnogram and a multiple sleep latency test rule out obstructive sleep apnea and confirm her diagnosis. She is started on a daytime medication that acts both by direct neurotransmitter release and reuptake inhibition. What other condition can this medication be used to treat?
- A. Obsessive-compulsive disorder
- B. Bulimia
- C. Attention-deficit hyperactivity disorder (Correct Answer)
- D. Tourette syndrome
- E. Alcohol withdrawal
Central disorders of hypersomnolence Explanation: ***Attention-deficit hyperactivity disorder***
- The patient's presentation is consistent with **narcolepsy type 2 (without cataplexy)**, given the excessive daytime sleepiness, short latency to REM sleep (immediate dreaming), and exclusion of sleep apnea. The medication described, acting via **direct neurotransmitter release and reuptake inhibition**, is characteristic of a stimulant like **methylphenidate** or an amphetamine-based drug.
- These stimulants are commonly used as first-line treatment for **attention-deficit hyperactivity disorder (ADHD)** due to their effects on dopamine and norepinephrine in the brain, improving focus and reducing impulsivity.
*Obsessive-compulsive disorder*
- **Obsessive-compulsive disorder (OCD)** is typically treated with selective serotonin reuptake inhibitors (SSRIs) or cognitive behavioral therapy.
- Stimulants are not indicated for OCD and may even worsen anxiety symptoms in some individuals.
*Bulimia*
- **Bulimia nervosa** is often managed with a combination of psychotherapy (e.g., cognitive behavioral therapy) and antidepressants like fluoxetine.
- Stimulants are not a primary treatment for bulimia and could potentially exacerbate some symptoms or risks due to their appetite-suppressing effects.
*Tourette syndrome*
- **Tourette syndrome** involves motor and vocal tics and is often treated with alpha-2 adrenergic agonists (e.g., guanfacine, clonidine) or dopamine receptor blocking agents.
- Stimulants generally are not used for Tourette syndrome as they can sometimes worsen tics.
*Alcohol withdrawal*
- **Alcohol withdrawal** is a medical emergency managed with benzodiazepines to prevent seizures and delirium tremens.
- Stimulants are contraindicated in alcohol withdrawal as they can increase seizure risk and cardiac complications.
Central disorders of hypersomnolence US Medical PG Question 3: A 16-year-old girl is brought to the physician because of generalized fatigue and an inability to concentrate in school for the past 4 months. During this period, she has had excessive daytime sleepiness. While going to sleep, she sees cartoon characters playing in her room. She wakes up once or twice every night. While awakening, she feels stiff and cannot move for a couple of minutes. She goes to sleep by 9 pm every night and wakes up at 7 am. She takes two to three 15-minute naps during the day and wakes up feeling refreshed. During the past week while listening to a friend tell a joke, she had an episode in which her head tilted and jaw dropped for a few seconds; it resolved spontaneously. Her father has schizoaffective disorder and her parents are divorced. Vital signs are within normal limits. Physical examination is unremarkable. Which of the following is the most appropriate initial pharmacotherapy?
- A. Modafinil (Correct Answer)
- B. Venlafaxine
- C. Risperidone
- D. Oral contraceptive pill
- E. Citalopram
Central disorders of hypersomnolence Explanation: ***Modafinil***
- This patient's symptoms (excessive daytime sleepiness, hypnagogic hallucinations, sleep paralysis, cataplexy, and refreshing naps) are highly suggestive of **narcolepsy**.
- **Modafinil** is a wake-promoting agent and is a first-line treatment for excessive daytime sleepiness in narcolepsy.
*Venlafaxine*
- **Venlafaxine** is a serotonin-norepinephrine reuptake inhibitor (SNRI) that can be used to treat cataplexy in narcolepsy by suppressing REM sleep.
- While cataplexy is present, the primary and most debilitating symptom is excessive daytime sleepiness, for which modafinil is the initial choice.
*Risperidone*
- **Risperidone** is an antipsychotic medication, primarily used to treat schizophrenia and bipolar disorder.
- Although the patient experiences hypnagogic hallucinations, these are part of narcolepsy symptoms and not indicative of a primary psychotic disorder warranting antipsychotic treatment.
*Oral contraceptive pill*
- An **oral contraceptive pill** is used for contraception or managing hormonal-related conditions such as irregular menstruation, acne, or polycystic ovary syndrome.
- There is no indication in the patient's presentation that would warrant treatment with oral contraceptives.
*Citalopram*
- **Citalopram** is a selective serotonin reuptake inhibitor (SSRI) and is typically used to treat depression or anxiety disorders.
- While sometimes used off-label for cataplexy in narcolepsy due to its REM-suppressing effects, it is not the initial treatment for the primary symptom of excessive daytime sleepiness.
Central disorders of hypersomnolence US Medical PG Question 4: A 23-year-old woman is seen by her primary care physician. The patient has a several year history of excessive daytime sleepiness. She also reports episodes where she suddenly falls to the floor after her knees become weak, often during a laughing spell. She has no other significant past medical history. Her primary care physician refers her for a sleep study, which confirms the suspected diagnosis. Which of the following laboratory findings would also be expected in this patient?
- A. Increased serum ESR
- B. Undetectable CSF hypocretin-1 (Correct Answer)
- C. Reduced serum hemoglobin
- D. Increased serum methemoglobin
- E. Increased CSF oligoclonal bands
Central disorders of hypersomnolence Explanation: ***Undetectable CSF hypocretin-1***
- The patient's symptoms of excessive daytime sleepiness and **cataplexy** (suddenly falling after knees become weak during laughing spells) are classic for **narcolepsy with cataplexy**.
- **Narcolepsy with cataplexy** is associated with the destruction of **hypocretin-producing neurons** in the hypothalamus, leading to undetectable levels of **hypocretin-1 (orexin A)** in the cerebrospinal fluid.
*Increased serum ESR*
- An **elevated erythrocyte sedimentation rate (ESR)** is a non-specific marker of inflammation and is not typically associated with narcolepsy.
- Inflammatory conditions such as **autoimmune diseases** or **infections** would cause an increased ESR.
*Reduced serum hemoglobin*
- **Reduced serum hemoglobin** indicates **anemia**, which is not a characteristic finding in narcolepsy with cataplexy.
- Anemia can cause fatigue but does not explain the episodes of cataplexy.
*Increased serum methemoglobin*
- **Methemoglobin** is an abnormal form of hemoglobin, and its increase (methemoglobinemia) is typically caused by exposure to certain **drugs or toxins**, not narcolepsy.
- It would lead to **cyanosis** and reduced oxygen carrying capacity, unrelated to the patient's symptoms.
*Increased CSF oligoclonal bands*
- **Oligoclonal bands in CSF** are indicative of **intrathecal immunoglobulin production** and are a hallmark finding in **multiple sclerosis (MS)**.
- While MS can cause fatigue, the specific presentation of cataplexy and excessive daytime sleepiness points away from MS as the primary diagnosis.
Central disorders of hypersomnolence US Medical PG Question 5: An 18-year-old man presents to his primary care physician with a complaint of excessive daytime sleepiness. He denies any substance abuse or major changes in his sleep schedule. He reports frequently dozing off during his regular daily activities. On further review of systems, he endorses falling asleep frequently with the uncomfortable sensation that there is someone in the room, even though he is alone. He also describes that from time to time, he has transient episodes of slurred speech when experiencing heartfelt laughter. Vital signs are stable, and his physical exam is unremarkable. This patient is likely deficient in a neurotransmitter produced in which part of the brain?
- A. Hippocampus
- B. Midbrain
- C. Pons nucleus
- D. Hypothalamus (Correct Answer)
- E. Thalamus
Central disorders of hypersomnolence Explanation: ***Hypothalamus***
- The patient's symptoms of excessive daytime sleepiness, cataplexy (falling asleep with strong emotions like laughter), and hypnagogic hallucinations (sensing someone in the room upon falling asleep) are classic for **narcolepsy**.
- Narcolepsy type 1 is characterized by a significant loss of **orexin (hypocretin)** neurons, a neuropeptide primarily produced in the **lateral hypothalamus** (specifically the lateral and perifornical areas), which plays a crucial role in maintaining wakefulness.
*Hippocampus*
- The **hippocampus** is primarily involved in **memory formation** and spatial navigation.
- Deficiencies in neurotransmitters produced or acting in the hippocampus are typically associated with memory disorders, not narcolepsy.
*Midbrain*
- The **midbrain** contains nuclei involved in dopamine, serotonin, and norepinephrine pathways, which are critical for mood, reward, and sleep-wake regulation.
- While these neurotransmitters influence the sleep-wake cycle, the primary deficiency in narcolepsy type 1 is specifically orexin, which originates from the hypothalamus, not the midbrain.
*Pons nucleus*
- The **pons** is essential for regulating sleep stages, particularly **REM sleep**, and contains nuclei involved in breathing and motor control.
- While it contributes to sleep architecture, the core pathology of narcolepsy type 1, the loss of orexin-producing neurons, is located higher in the brain, in the hypothalamus.
*Thalamus*
- The **thalamus** acts as a crucial relay station for sensory and motor signals to the cerebral cortex and is involved in regulating consciousness and alertness.
- While it is involved in arousal regulation, it is not the primary site of orexin production, nor is a neurotransmitter deficiency directly from the thalamus the primary cause of narcolepsy.
Central disorders of hypersomnolence US Medical PG Question 6: A 72-year-old man presents to his primary care physician complaining of increasing difficulty sleeping over the last 3 months. He reports waking up frequently during the night because he feels an urge to move his legs, and he has a similar feeling when watching television before bed. The urge is relieved by walking around or rubbing his legs. The patient’s wife also notes that she sometimes sees him moving his legs in his sleep and is sometimes awoken by him. Due to his recent sleep troubles, the patient has started to drink more coffee throughout the day to stay awake and reports having up to 3 cups daily. The patient has a past medical history of hypertension and obesity but states that he has lost 10 pounds in the last 3 months without changing his lifestyle. He is currently on hydrochlorothiazide and a multivitamin. His last colonoscopy was when he turned 50, and he has a family history of type II diabetes and dementia. At this visit, his temperature is 99.1°F (37.3°C), blood pressure is 134/81 mmHg, pulse is 82/min, and respirations are 14/min. On exam, his sclerae are slightly pale. Cardiovascular and pulmonary exams are normal, and his abdomen is soft and nontender. Neurologic exam reveals 2+ reflexes in the bilateral patellae and 5/5 strength in all extremities. Which of the following is most likely to identify the underlying etiology of this patient's symptoms?
- A. Colonoscopy (Correct Answer)
- B. Trial of iron supplementation
- C. Trial of reduction in caffeine intake
- D. Trial of pramipexole
- E. Dopamine uptake scan of the brain
Central disorders of hypersomnolence Explanation: ***Colonoscopy***
- The patient presents with **classic restless legs syndrome (RLS)** symptoms along with multiple red flags: **unexplained 10-pound weight loss**, **pale sclerae** suggesting anemia, and a **remote last colonoscopy 22 years ago**.
- These findings raise significant concern for **gastrointestinal malignancy** (particularly colon cancer) causing chronic occult blood loss, leading to **iron deficiency anemia**, which is a well-known secondary cause of RLS.
- **Colonoscopy is the definitive diagnostic test** that would identify the underlying etiology (e.g., colon cancer, other GI bleeding source) causing the iron deficiency and subsequent RLS symptoms.
- At age 72 with the last colonoscopy at age 50, the patient is significantly overdue for colorectal cancer screening, making this investigation both urgent and appropriate.
*Trial of iron supplementation*
- While iron deficiency is likely contributing to the RLS symptoms, a **therapeutic trial does not identify the underlying etiology** - it only treats the consequence.
- Given the concerning red flags (weight loss, anemia, overdue screening), it would be premature to simply supplement iron without investigating the **source of iron loss**, which could be a malignancy.
- Iron supplementation may temporarily improve RLS but would delay diagnosis of a potentially serious underlying condition.
*Trial of reduction in caffeine intake*
- While caffeine can exacerbate RLS symptoms, the patient only increased coffee intake **after** developing sleep problems (as a compensatory mechanism).
- The presence of weight loss and anemia indicates a more serious underlying pathology that would not be addressed by reducing caffeine.
- Caffeine reduction alone would not identify any underlying etiology.
*Trial of pramipexole*
- Pramipexole is a **dopamine agonist** used for symptomatic treatment of RLS.
- However, it is important to **identify and treat secondary causes** (like iron deficiency from GI blood loss) before initiating dopaminergic therapy.
- This would be premature without first investigating the red flag symptoms suggesting serious underlying pathology.
*Dopamine uptake scan of the brain*
- A **DAT scan** is used to differentiate Parkinson's disease from essential tremor or other movement disorders, which is not relevant here.
- RLS is a **clinical diagnosis** based on symptoms, and dopamine imaging is not indicated for RLS diagnosis or workup.
- This test would not identify the underlying etiology of this patient's symptoms.
Central disorders of hypersomnolence US Medical PG Question 7: A 21-year-old man presents to the clinic complaining of feeling tired during the day. He is concerned as his grades in school have worsened and he does not want to lose his scholarship. Upon further questioning, the patient describes frequently experiencing a dreamlike state before falling asleep and after waking up. He also has frequent nighttime awakenings where he finds himself unable to move. He denies snoring. The patient does not drink alcohol or abuse any other drugs. The patient's BMI is 21 kg/m2, and his vital signs are all within normal limits. What is this patient's diagnosis?
- A. Obstructive sleep apnea (OSA)
- B. Insomnia
- C. Alcohol withdrawal
- D. Delayed sleep phase syndrome (DSPS)
- E. Narcolepsy (Correct Answer)
Central disorders of hypersomnolence Explanation: ***Narcolepsy***
- The patient's symptoms of **excessive daytime sleepiness**, **hypnagogic/hypnopompic hallucinations** (dreamlike state before falling asleep and after waking up), and **sleep paralysis** (unable to move during nighttime awakenings) are the **classic tetrad of narcolepsy** (cataplexy is the 4th feature, not present here).
- The absence of snoring, normal BMI, and lack of alcohol/drug use rule out other common causes of sleep disturbances, supporting the diagnosis of narcolepsy.
- Narcolepsy is a **chronic sleep-wake disorder** caused by hypothalamic hypocretin (orexin) deficiency.
*Obstructive sleep apnea (OSA)*
- While OSA also causes **daytime sleepiness**, a key feature is **snoring**, which this patient denies.
- OSA is often associated with obesity, but this patient has a **normal BMI of 21 kg/m²**.
- OSA would not explain the hypnagogic hallucinations or sleep paralysis.
*Insomnia*
- Insomnia primarily involves difficulty initiating or maintaining sleep, leading to **insufficient sleep quantity or quality**.
- This patient's symptoms are more specific, including episodes of sleep paralysis and vivid dreamlike states, rather than just general difficulty sleeping.
- The hallmark features of narcolepsy distinguish this from simple insomnia.
*Alcohol withdrawal*
- Alcohol withdrawal can cause **sleep disturbances**, but it is typically accompanied by other symptoms like tremors, anxiety, autonomic hyperactivity, and potentially seizures, none of which are present.
- The patient **explicitly denies drinking alcohol**, making this diagnosis highly unlikely.
*Delayed sleep phase syndrome (DSPS)*
- DSPS is a **circadian rhythm disorder** characterized by a delayed sleep-wake cycle, where individuals fall asleep and wake up later than desired.
- While it can cause daytime fatigue if individuals are forced to wake up early, it does **not** involve the specific symptoms of hypnagogic/hypnopompic hallucinations or sleep paralysis seen in this patient.
- DSPS is primarily a timing issue, not a neurological sleep disorder.
Central disorders of hypersomnolence US Medical PG Question 8: A 50-year-old man with severe obstructive sleep apnea (AHI 65 events/hour) and CPAP intolerance despite multiple mask trials undergoes maxillomandibular advancement surgery. Three months post-operatively, he continues to report excessive daytime sleepiness and his bed partner reports persistent snoring. Post-operative polysomnography shows AHI of 28 events/hour. He has a BMI of 38 kg/m² (unchanged from pre-surgery) and crowded posterior pharynx. Evaluate the next management strategy.
- A. Hypoglossal nerve stimulation therapy evaluation
- B. Repeat maxillomandibular advancement with greater advancement distance
- C. Observe for another 3 months as surgical swelling may still be resolving
- D. Revisit CPAP therapy with auto-adjusting pressure settings (Correct Answer)
- E. Proceed directly to tracheostomy for definitive airway management
Central disorders of hypersomnolence Explanation: ***Revisit CPAP therapy with auto-adjusting pressure settings***
- **Maxillomandibular advancement (MMA)** significantly reduced the **Apnea-Hypopnea Index (AHI)** from 65 to 28; while not curative, this anatomical change may lower the **positive airway pressure (PAP)** requirements, potentially improving **patient tolerance**.
- **Auto-CPAP** is the most appropriate next step to determine if the post-surgical airway allows for successful treatment at manageable pressures, especially before considering more invasive options.
*Hypoglossal nerve stimulation therapy evaluation*
- This patient's **BMI of 38 kg/m²** currently exceeds the standard FDA-approved threshold of **35 kg/m²** for **hypoglossal nerve stimulation**.
- Evaluation requires a **Drug-Induced Sleep Endoscopy (DISE)** to check for **concentric palatal collapse**, but primary medical optimization remains the priority.
*Repeat maxillomandibular advancement with greater advancement distance*
- **Revision MMA** carries significantly higher surgical risks, including **nerve injury** and **non-union**, and is generally not indicated when initial surgery was technically successful.
- The persistent **AHI of 28** is more likely due to the patient's **persistent obesity** and soft tissue volume rather than inadequate bony advancement.
*Observe for another 3 months as surgical swelling may still be resolving*
- Three months is typically sufficient for the resolution of **post-operative edema** impacting the airway, and active treatment is needed for **moderate OSA** (AHI 28) and **daytime sleepiness**.
- Delaying management puts the patient at continued risk for **cardiovascular complications** and accidents associated with **excessive sleepiness**.
*Proceed directly to tracheostomy for definitive airway management*
- **Tracheostomy** is the most invasive surgical intervention and is reserved for **life-threatening OSA** where all other medical and surgical options have failed.
- It represents a significant **quality-of-life burden** and should not be considered until less invasive modalities like post-surgical **PAP therapy** are re-attempted.
Central disorders of hypersomnolence US Medical PG Question 9: A 70-year-old man with newly diagnosed Parkinson disease and REM sleep behavior disorder is being considered for treatment. His neurologist is concerned about medication interactions and disease progression. He also has mild cognitive impairment, orthostatic hypotension, and a history of visual hallucinations. Evaluate the optimal therapeutic approach considering his complex medical profile.
- A. Quetiapine for both hallucinations and RBD symptoms
- B. Clonazepam 0.5 mg at bedtime with close monitoring for falls
- C. Rivastigmine to address cognitive impairment and sleep disturbance
- D. Melatonin 3-12 mg at bedtime as first-line therapy (Correct Answer)
- E. Pramipexole dose adjustment to suppress REM sleep
Central disorders of hypersomnolence Explanation: ***Melatonin 3-12 mg at bedtime as first-line therapy***
- **Melatonin** is the preferred first-line treatment for **REM sleep behavior disorder (RBD)** in elderly patients with neurodegeneration due to its excellent safety profile.
- It effectively reduces **dream enactment** with a lower risk of side effects like **excessive sedation** or motor instability compared to other agents.
*Quetiapine for both hallucinations and RBD symptoms*
- While **Quetiapine** is used to manage **visual hallucinations** in Parkinson's, it is not an established or effective therapy for managing **RBD symptoms**.
- It may worsen **orthostatic hypotension** and daytime somnolence, complicating the patient's existing clinical state.
*Clonazepam 0.5 mg at bedtime with close monitoring for falls*
- **Clonazepam** is highly effective for RBD but is generally avoided in patients with **mild cognitive impairment** and **orthostatic hypotension** due to the high risk of **confusion** and **falls**.
- It can also exacerbate **obstructive sleep apnea** or cause significant **morning-after sedation** in the elderly.
*Rivastigmine to address cognitive impairment and sleep disturbance*
- **Rivastigmine**, a cholinesterase inhibitor, is used for **Parkinson disease dementia** but is not the primary treatment for **REM sleep behavior disorder**.
- Although it may help cognitive symptoms, it does not reliably suppress the physical **dream enactment** characteristic of RBD.
*Pramipexole dose adjustment to suppress REM sleep*
- **Dopamine agonists** like **Pramipexole** are known to potentially **worsen RBD** and can significantly increase the frequency of **visual hallucinations**.
- Increasing the dose in this patient would likely exacerbate his **psychosis** and **orthostatic hypotension**.
Central disorders of hypersomnolence US Medical PG Question 10: A 25-year-old medical resident presents with excessive daytime sleepiness and difficulty maintaining wakefulness during lectures. Polysomnography shows normal sleep architecture with a sleep latency of 8 minutes. Multiple Sleep Latency Test (MSLT) shows a mean sleep latency of 4 minutes with 1 sleep-onset REM period (SOREMP). She works rotating shifts, sleeps 4-5 hours on workdays, and has no cataplexy. Evaluation of this clinical scenario suggests which diagnosis best accounts for all findings?
- A. Idiopathic hypersomnia with long sleep time
- B. Narcolepsy type 1 requiring CSF hypocretin measurement
- C. Shift work sleep disorder with circadian misalignment
- D. Narcolepsy type 2 based on objective sleepiness and one SOREMP
- E. Insufficient sleep syndrome related to work schedule (Correct Answer)
Central disorders of hypersomnolence Explanation: ***Insufficient sleep syndrome related to work schedule***
- The patient reports sleeping only **4-5 hours** on workdays, which represents chronic **sleep restriction** compared to the physiological requirement of 7-9 hours.
- **Chronic sleep deprivation** can lead to a shortened mean sleep latency of <8 minutes and single **SOREMPs** on MSLT, making it the most plausible explanation for the findings in a medical resident.
*Idiopathic hypersomnia with long sleep time*
- This condition is characterized by a mean sleep latency of <8 minutes but typically involves **prolonged sleep episodes** (more than 10-11 hours) with significant **sleep drunkenness**.
- The diagnosis requires ruling out **insufficient sleep**, and this patient’s restricted 4-5 hour sleep window directly contradicts the "long sleep time" criteria.
*Narcolepsy type 1 requiring CSF hypocretin measurement*
- **Narcolepsy Type 1** requires the presence of **cataplexy** or low **CSF hypocretin-1** levels, neither of which is suggested by the patient's history.
- The MSLT results in this case only showed **one SOREMP**, whereas Narcolepsy Type 1 diagnosis usually requires **two or more SOREMPs** (or one SOREMP during polysomnography and one during MSLT).
*Shift work sleep disorder with circadian misalignment*
- While the patient works rotating shifts, this disorder specifically involves insomnia or sleepiness that is temporally linked to the **work schedule** causing **circadian misalignment**.
- The primary issue here is the **quantity of sleep** (4-5 hours) rather than the timing of sleep relative to her internal clock, pointing more specifically to insufficient sleep syndrome.
*Narcolepsy type 2 based on objective sleepiness and one SOREMP*
- Diagnostic criteria for **Narcolepsy Type 2** require a mean sleep latency of ≤8 minutes and **two or more SOREMPs**; this patient only had one SOREMP.
- A diagnosis of Narcolepsy Type 2 cannot be made until **insufficient sleep syndrome** is ruled out by ensuring adequate sleep hygiene for at least two weeks prior to testing.
More Central disorders of hypersomnolence US Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
